Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Wedbush

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Wedbush

Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $71.00 to $55.00 and set an "outperform" rating on the stock in a research note on Friday.

Why This Biotech Just Nearly Erased Its One-Day 50% Pop

Xenon Pharmaceuticals halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed.

The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone

Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low.

Xenon Pharmaceuticals (XENE) Plunges 25% on Psychiatric Trial Halt: Is Now the Time to Buy?

Xenon Pharmaceuticals (XENE) stock plummeted 25% after pausing psychiatric trials due to adverse events, though it filed for epilepsy drug approval.

Is Xenon Pharmaceuticals (XENE) Stock a Buy After Its Worst Drop in Nearly a Decade?

TLDR Xenon submitted a New Drug Application for azetukalner in focal seizures, marking a potential first commercial product The company paused new patient enrollment in major depressive disorder and bipolar depression trials due to neuropsychiatric adverse events XENE stock dropped 25% to $42.84 in...

Robert W. Baird Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target decreased by analysts at Robert W. Baird from $97.00 to $90.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price objective indicates a potential upside of 56.93% from the […]